Treviamet 50mg/500mg

Indication

Treviamet (Sitagliptin 50 mg + Metformin HCl 500 mg) is a fixed-dose combination antidiabetic for type 2 diabetes mellitus, providing complementary dual mechanisms: Sitagliptin (DPP-4 inhibitor) increases incretin levels, and Metformin reduces hepatic glucose production and improves insulin sensitivity.

Ingredients

• Sitagliptin
• Metformin HCl

Direction

Adults: 1 tablet (Sitagliptin 50 mg/Metformin 500 mg) twice daily with meals to reduce GI side effects. Dose adjusted by physician based on glycaemic control and renal function.

Side effects

• Nausea
• diarrhea
• abdominal pain (metformin)
• Nasopharyngitis
• upper respiratory infection (sitagliptin)
• Headache
• Hypoglycaemia (with sulfonylureas or insulin)
• Lactic acidosis (rare — metformin)
• Pancreatitis (rare)

Precautions

• Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²).
• Withhold before and 48 hours after use of iodinated contrast media.
• Risk of lactic acidosis from metformin
• avoid in renal
• hepatic impairment
• and excessive alcohol use.
• May cause pancreatitis
• discontinue if severe abdominal pain occurs.
• Not for type 1 diabetes or diabetic ketoacidosis.
• Monitor renal function regularly.
• Keep out of reach of children.